Thomas B. Leonard

2.4k total citations
65 papers, 1.8k citations indexed

About

Thomas B. Leonard is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pharmacology. According to data from OpenAlex, Thomas B. Leonard has authored 65 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 14 papers in Physiology and 13 papers in Pharmacology. Recurrent topics in Thomas B. Leonard's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (22 papers), Pharmacogenetics and Drug Metabolism (10 papers) and Sarcoidosis and Beryllium Toxicity Research (9 papers). Thomas B. Leonard is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (22 papers), Pharmacogenetics and Drug Metabolism (10 papers) and Sarcoidosis and Beryllium Toxicity Research (9 papers). Thomas B. Leonard collaborates with scholars based in United States, Germany and United Kingdom. Thomas B. Leonard's co-authors include James A. Popp, Douglas W.P. Hay, Robin E. Buckingham, M. Dawn McArthur, Diane T. Finegood, Brian Topp, Reynold A. Panettieri, Mark A. Luttmann, Vincenzo Ciocca and John G. Dent and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Hepatology.

In The Last Decade

Thomas B. Leonard

59 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas B. Leonard United States 20 572 555 547 306 215 65 1.8k
Patricia C. Chulada United States 15 322 0.6× 208 0.4× 403 0.7× 240 0.8× 268 1.2× 22 2.2k
Paul Rubin United States 18 969 1.7× 622 1.1× 425 0.8× 193 0.6× 172 0.8× 39 1.8k
Richard I. Sperling United States 16 649 1.1× 298 0.5× 444 0.8× 614 2.0× 323 1.5× 21 2.6k
Martin Kömhoff Germany 25 168 0.3× 248 0.4× 730 1.3× 163 0.5× 257 1.2× 55 2.0k
Luı́s Vila Spain 24 195 0.3× 222 0.4× 412 0.8× 299 1.0× 326 1.5× 62 1.7k
Atsushi Tatsuguchi Japan 23 224 0.4× 343 0.6× 461 0.8× 822 2.7× 106 0.5× 95 2.0k
Emile Levy Canada 21 341 0.6× 182 0.3× 457 0.8× 281 0.9× 123 0.6× 41 1.4k
Taketoshi Kishimoto Japan 25 100 0.2× 319 0.6× 723 1.3× 361 1.2× 190 0.9× 97 2.1k
Jun Shi China 21 285 0.5× 169 0.3× 714 1.3× 356 1.2× 291 1.4× 60 2.0k
Janice R. Okita United States 22 129 0.2× 285 0.5× 399 0.7× 144 0.5× 198 0.9× 33 1.7k

Countries citing papers authored by Thomas B. Leonard

Since Specialization
Citations

This map shows the geographic impact of Thomas B. Leonard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas B. Leonard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas B. Leonard more than expected).

Fields of papers citing papers by Thomas B. Leonard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas B. Leonard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas B. Leonard. The network helps show where Thomas B. Leonard may publish in the future.

Co-authorship network of co-authors of Thomas B. Leonard

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas B. Leonard. A scholar is included among the top collaborators of Thomas B. Leonard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas B. Leonard. Thomas B. Leonard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Knutson, K., Andrew C. Peterson, Thomas B. Leonard, et al.. (2024). Talar and Calcaneal Coordinate Axes Definitions across Foot Pathologies. Journal of Biomechanics. 175. 112298–112298. 3 indexed citations
2.
Swaminathan, Aparna, Timothy P. Whelan, Megan L. Neely, et al.. (2024). Association of Quantitative Lung Fibrosis (QLF) Score With the Severity and Progression of Progressive Pulmonary Fibrosis (PPF). A5085–A5085.
3.
Summer, Ross, Jamie L. Todd, Megan L. Neely, et al.. (2024). Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respiratory Research. 25(1). 58–58. 15 indexed citations
4.
Sack, Coralynn, Daniel Wojdyla, Amanda J. Gassett, et al.. (2024). Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Annals of the American Thoracic Society. 22(3). 378–386. 5 indexed citations
5.
Astor, Todd L., Hilary J. Goldberg, Laurie D. Snyder, et al.. (2023). Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease. 17. 2683745240–2683745240. 4 indexed citations
6.
Andrade, João A. de, Megan L. Neely, Anne S. Hellkamp, et al.. (2023). Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis. Clinical Therapeutics. 45(4). 306–315. 16 indexed citations
7.
Snyder, Laurie D., Megan L. Neely, Anne S. Hellkamp, et al.. (2022). Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 200(1). 21–29. 7 indexed citations
8.
Todd, Jamie L., Richard Vinisko, Yi Liu, et al.. (2020). Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. BMC Pulmonary Medicine. 20(1). 64–64. 68 indexed citations
9.
Salisbury, Margaret L., Craig Conoscenti, Daniel A. Culver, et al.. (2020). Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Annals of the American Thoracic Society. 17(11). 1413–1423. 33 indexed citations
10.
Todd, Jamie L., Megan L. Neely, Robert Overton, et al.. (2019). Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respiratory Research. 20(1). 227–227. 60 indexed citations
11.
Snyder, Laurie D., Megan L. Neely, Anne S. Hellkamp, et al.. (2019). Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respiratory Research. 20(1). 105–105. 50 indexed citations
12.
Tashkin, Donald P., Eric Bateman, Paul Jones, et al.. (2016). Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. Respiratory Medicine. 120. 91–100. 4 indexed citations
13.
Tashkin, Donald P., Paul Jones, Thomas B. Leonard, et al.. (2014). Tiotropium Delivered via HandiHaler or Respimat: Improvement in Health-Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease. CHEST Journal. 146(4). 49A–49A. 1 indexed citations
14.
Amory, John K., et al.. (2007). MER-104 tablets: a dose-ranging study of an oral formulation of a gonadotropin-releasing hormone antagonist, acyline.. Molecular Cancer Therapeutics. 6. 2 indexed citations
15.
Birrell, Mark A., Matthew C. Catley, Elizabeth Hardaker, et al.. (2007). Novel Role for the Liver X Nuclear Receptor in the Suppression of Lung Inflammatory Responses. Journal of Biological Chemistry. 282(44). 31882–31890. 53 indexed citations
16.
Szulakowski, Patryk, Luis A. Jiménez, Kenneth Donaldson, et al.. (2006). The Effect of Smoking on the Transcriptional Regulation of Lung Inflammation in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 174(1). 41–50. 141 indexed citations
17.
18.
Kroll, David J., M. Elizabeth Graichen, & Thomas B. Leonard. (1988). Strain difference in rat renal microsomal epoxide hydrolase elevation after mercuric chloride treatment. Carcinogenesis. 9(2). 193–198. 1 indexed citations
19.
Farber, John L., et al.. (1988). Peroxidation-dependent and peroxidation-independent mechanisms by which acetaminophen kills cultured rat hepatocytes. Archives of Biochemistry and Biophysics. 267(2). 640–650. 35 indexed citations
20.
Duignan, David B., I.G. Sipes, Thomas B. Leonard, & James R. Halpert. (1986). Purification and characterization of the dog hepatic cytochrome P-450 isozyme(s) responsible for the metabolism of 2,2',4,4',5,5'-hexachlorobiphenyl. Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States). 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patricia C. Chulada Breakdown of academic impact, for papers by Paul Rubin Breakdown of academic impact, for papers by Richard I. Sperling Breakdown of academic impact, for papers by Martin Kömhoff Breakdown of academic impact, for papers by Luı́s Vila Breakdown of academic impact, for papers by Atsushi Tatsuguchi Breakdown of academic impact, for papers by Emile Levy Breakdown of academic impact, for papers by Taketoshi Kishimoto Breakdown of academic impact, for papers by Jun Shi Breakdown of academic impact, for papers by Janice R. Okita
Rankless by CCL
2026